Even more concerning is the approval of the DNA vaccine of Cadila Healthcare in India for children in the 12-18 age group based on a small subset of data, without biodistribution studies and without evaluation of long-term safety aspects in children.
The pandemic has had a severe impact on provision of eye care facilities across the country which further led to increasing cases of eye problems.
Covaxin, indigenously developed by BBIL in collaboration with the Indian Council of Medical Research (ICMR), is being used on adults in India’s ongoing COVID-19 vaccination drive.
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20.
India to soon roll out clinical trials on 750 hospitalised adult patients as part WHO Solidarity trialOct 05, 2021
The WHO Solidarity PLUS Trial aims to evaluate three treatment arms -Artesunate, Infliximab and Imatinib, in addition to the local standard of care.
Though efficacy of ZyCoV-D was 67% compared to mRNA vaccine and others which is about 90%, there have not been late stage trials which Zydus Cadila has promised to publish at a later date.